The authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors. This project was funded by a grant from the American Cancer Society (RSG-11-098-01-CPHPS to Dr. Neuner).
Yen TW, Czypinski LK, Sparapani RA et al.. Socioeconomic factors associated with adjuvant hormone therapy use in older breast cancer survivors. Cancer 2011;117:398–405.
Amir E, Seruga B, Niraula S et al.. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst 2011;103:1299–1309.
Neuner JM, Yen TW, Sparapani RA et al.. Fracture risk and adjuvant hormonal therapy among a population-based cohort of older female breast cancer patients. Osteoporos Int 2011;22:2847–2855.
Lonning PE, Geisler J, Krag LE et al.. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005;23:5126–5137.
Gralow JR, Biermann JS, Farooki A et al.. NCCN Task Force Report: Bone Health In Cancer Care. J Natl Compr Canc Netw 2013;11(Suppl 3):S1–50.
Hillner BE, Ingle JN, Chlebowski RT et al.. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042–4057.
Lim LS, Hoeksema LJ, Sherin K. Screening for osteoporosis in the adult U.S. population: ACPM position statement on preventive practice. Am J Prev Med 2009;36:366–375.
Nelson HD, Haney EM, Dana T et al.. Screening for osteoporosis: an update for the U.S. Preventive Services Task Force. Ann Intern Med 2010;153:99–111.
Earle CC, Burstein HJ, Winer EP et al.. Quality of non–breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol 2003;21:1447–1451.
Snyder CF, Frick KD, Kantsiper ME et al.. Prevention, screening, and surveillance care for breast cancer survivors compared with controls: changes from 1998 to 2002. J Clin Oncol 2009;27:1054–1061.
Ligibel J, O'Malley AJ, Fisher M et al.. Patterns of bone density evaluation in a community population treated with aromatase inhibitors. Breast Cancer Res Treat 2012;134:1305–1313.
Spangler L, Yu O, Loggers E et al.. Bone mineral density screening among women with a history of breast cancer treated with aromatase inhibitors. J Women's Health 2013;22:132–140.
Early Breast Cancer Trialists' Collaborative Group: aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 2015;386:1341–1352.
Nattinger AB, Laud PW, Bajorunaite R et al.. An algorithm for the use of Medicare claims data to identify women with incident breast cancer. Health Serv Res 2004;39(6 Pt 1):1733–1749.
Klabunde CN, Legler JM, Warren JL et al.. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol 2007;17:584–590.
Howell A, Cuzick J, Baum M et al.. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60–62.
van de Velde CJ, Rea D, Seynaeve C et al.. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 2011;377:321–331.
Dhesy-Thind SK. Screening for osteoporosis in postmenopausal women with breast cancer receiving aromatase inhibitors: less is more? J Clin Oncol 2012;30:1408–1410.
Jacobsen SJ, Goldberg J, Miles TP et al.. Hip fracture incidence among the old and very old: a population-based study of 745,435 cases. Am J Public Health 1990;80:871–873.
Hui SL, Slemenda CW, Johnston CC. Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 1988;81:1804–1809.
Banks E, Reeves GK, Beral V et al.. Hip fracture incidence in relation to age, menopausal status, and age at menopause: prospective analysis. PLOS Med 2009;6:e1000181.
Neuner JM, Binkley N, Sparapani RA et al.. Bone density testing in older women and its association with patient age. J Am Geriatr Soc 2006;54:485–489.
Curtis JR, Carbone L, Cheng H et al.. Longitudinal trends in use of bone mass measurement among older americans, 1999-2005. J Bone Miner Res 2008;23:1061–1067.
Aft R, Naughton M, Trinkaus K et al.. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 2010;11:421–428.
Gnant M, Mlineritsch B, Stoeger H et al.. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 2011;12:631–641.
Eidtmann H, de Boer R, Bundred N et al.. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 2010;21:2188–2194.
Persson I, Adami HO, McLaughlin JK et al.. Reduced risk of breast and endometrial cancer among women with hip fractures (Sweden). Cancer Causes Control 1994;5:523–528.
Newcomb PA, Trentham-Dietz A, Egan KM et al.. Fracture history and risk of breast and endometrial cancer. Am J Epidemiol 2001;153:1071–1078.
Ganry O, Peng J, Dubreuil A. Is there a reduced risk of breast cancer among women with hip fractures? Eur J Epidemiol 1999;15:313–315.
Chen Z, Maricic M, Aragaki A et al.. Fracture risk increases after diagnosis of breast or other cancers in postmenopausal women: results from the Women's Health Initiative. Osteoporos Int 2009;20:527–536.
Ito K, Blinder VS, Elkin EB. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer. J Clin Oncol 2012;30:1468–1475.